Delhi Capitals enter IPL 2025 with Axar Patel as the new captain, featuring star signings like KL Rahul and Mitchell Starc. The team aims to secure their first IPL title with a powerful batting ...

Kolkata Knight Riders aim to secure their fourth IPL title with Ajinkya Rahane as the new captain. Retaining key players like Sunil Narine and Andre Russell, and adding talents such as Quinton de ...

Strengths: Mumbai Indians boast of a powerful batting line-up. It is among the few sides whose top and middle-order is almost completely filled with international stars. The side already had T20I ...

Kolkata Knight Riders (KKR) enter the Indian Premier League (IPL) 2025 season as the reigning champions, having pulled off arguably the most dominant campaign in IPL history in 2024. Despite the ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Michael is a full-time senior editor of investing and trading products for ...

Mumbai Indians are ready to start their Indian Premier League (IPL) 2025 campaign in search of their sixth title. They have the joint-most number of trophies (5) in the history of IPL. (More ...

The Indian Premier League (IPL) 2025 is almost here. Kolkata Knight Riders are ready to defend their crown while the other nine teams too are ready to challenge the defending champions. (Full ...

Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer, in non ...

Regeneron Pharmaceuticals, Inc. is a well-managed company with a diverse pipeline, but faces the likely decline in revenues from its key drug, Eylea. The loss of Eylea's patent protection has led ...

Solnerstotug showed a 14% response rate and 62% disease control in PD-L1 resistant tumors, surpassing typical expectations. Significant responses were observed in Merkel cell carcinoma and ...

CAMBRIDGE, Mass. - Immuneering Corporation (NASDAQ:IMRX), a clinical-stage biotech company with a current market capitalization of $52 million focused on developing therapies for cancer treatment, has ...